Cargando…
Repeatability of tumor blood flow quantification with (82)Rubidium PET/CT in prostate cancer — a test-retest study
BACKGROUND: Non-invasive tumor blood flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. Validation data have recently been published on prostate TBF measurement with the widely used positron emission tomography (PET) flow tracer (82)...
Autores principales: | Jochumsen, Mads Ryø, Bouchelouche, Kirsten, Nielsen, Katrine Bødkergaard, Frøkiær, Jørgen, Borre, Michael, Sörensen, Jens, Tolbod, Lars Poulsen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609677/ https://www.ncbi.nlm.nih.gov/pubmed/31273483 http://dx.doi.org/10.1186/s13550-019-0529-2 |
Ejemplares similares
-
Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
por: Jochumsen, Mads Ryø, et al.
Publicado: (2020) -
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness
por: Jochumsen, Mads Ryø, et al.
Publicado: (2021) -
Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by (68)Ga-PSMA PET/CT
por: Christensen, Mads T., et al.
Publicado: (2022) -
Rubidium-82 PET/CT in COVID-19
por: van de Burgt, Alina, et al.
Publicado: (2021) -
Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging
por: Chatal, Jean-François, et al.
Publicado: (2015)